

Title: A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration.

Protocol Number: ONL1204-GA-002

Condition: Geographic Atrophy (GA) associated with Age-Related Macular Degeneration

Eligible Subjects will be randomly assigned into one of the six study arms:

Arm A: Single intravitreal injection of ONL1204 200 µg, 100 µL every 12 weeks through end of study at 72 weeks for a total of 6 injections.

Arm B: Single intravitreal injection of ONL1204 100 µg, 50 µL every 12 weeks through end of study at 72 weeks for a total of 6 injections.

Arm C: Single injection of Sham every 12 weeks through end of study at 72 weeks for a total of 6 Sham injections.

Arm D: Single intravitreal injection of ONL1204 200 µg, 100 µL every 24 weeks through end of study at 72 weeks for a total of 3 injections.

Arm E: Single injection of Sham every 24 weeks through end of study at 72 weeks for a total of 3 Sham injections.

Arm F: Single intravitreal injection of Avacincaptad Pegol 2 mg, 0.1 mL of 20 mg/mL solution every month through end of study at 72 weeks for a total of 18 injections.

Final Visit for all Arms: Week 72

Sponsor: ONL Therapeutics, Inc.

Royal Oak Site:

Principal Investigator: Antonio Capone Jr., M.D.

Coordinators: Dawn Gedvilas

248-288-9132 ext. 1334

Naina Desai

248-288-9132 ext. 1315